Desipramine Shortage: What Providers and Prescribers Need to Know in 2026

This post is written for clinicians — primary care providers, psychiatrists, neurologists, NPs, and PAs — who prescribe desipramine and are fielding questions from patients who cannot reliably fill it. We cover the current supply situation, prescribing context, clinical alternatives, and practical workflows to reduce patient disruption.

Current Desipramine Supply Status (2026)

Desipramine hydrochloride is not currently listed as an active shortage on the FDA Drug Shortage Database. Generic tablets are available from multiple manufacturers in strengths of 10, 25, 50, 75, 100, and 150 mg. The original brand Norpramin is largely discontinued in the U.S. market.

Despite the absence of a formal shortage designation, a subset of patients continue to report difficulty filling their prescriptions — particularly for less common strengths (10 mg and 75 mg) and in rural or underserved areas. The root causes are structural: desipramine's declining prescription volume has reduced manufacturer incentives to maintain robust supply buffers, and a limited number of generic producers means regional disruptions have an outsized effect on patients.

Prescribing Context: Who Is Still on Desipramine?

Desipramine is FDA-approved only for the treatment of depression in adults. In clinical practice, it remains relevant in several specific populations:

Treatment-resistant depression: Patients who have failed multiple SSRI/SNRI trials and are on a TCA for its noradrenergic mechanism.

ADHD (off-label): Patients unable to tolerate stimulants or with contraindications to controlled substances. Desipramine's norepinephrine reuptake inhibition parallels the mechanism of atomoxetine.

Neuropathic pain and fibromyalgia (off-label): Desipramine's noradrenergic activity modulates descending pain inhibitory pathways.

Bulimia nervosa (off-label): Evidence supports short-term efficacy; may be considered when first-line agents are inadequate.

Long-term stable patients: Some patients have been on desipramine for years and are well-stabilized — switching is not always appropriate or desirable.

Clinical Alternatives When Desipramine Is Unavailable

If a patient cannot access desipramine and a therapeutic substitution is necessary, consider the following based on the primary indication:

For depression:

Nortriptyline: The most structurally similar TCA; secondary amine; similar NE selectivity; widely available; well-studied with therapeutic drug monitoring (TDM) target of 50–150 ng/mL

Imipramine: Tertiary amine TCA; desipramine is its active metabolite; widely available; more anticholinergic and sedating; less preferred in elderly

SNRI (venlafaxine or duloxetine): If the clinical rationale was noradrenergic augmentation, an SNRI may provide overlapping benefit with a cleaner tolerability profile

For ADHD (off-label):

Atomoxetine (Strattera): FDA-approved NRI for ADHD; non-stimulant; shares mechanistic basis with desipramine; requires titration

Viloxazine (Qelbree): FDA-approved NRI for ADHD; newer agent with favorable tolerability data

For neuropathic pain:

Nortriptyline: Also used for neuropathic pain; similar mechanism; widely available

Duloxetine: FDA-approved for diabetic peripheral neuropathy; also used for fibromyalgia

TCA Switching Protocol: Key Clinical Points

When switching between TCAs or from a TCA to another agent, keep the following in mind:

Taper desipramine gradually — abrupt discontinuation can cause cholinergic rebound (nausea, diaphoresis, dizziness) and mood instability

At least 14 days washout required before starting any MAOI after desipramine (and vice versa)

If switching to fluoxetine, allow at least 5 weeks after fluoxetine discontinuation before starting desipramine due to CYP2D6 inhibition

Consider ECG screening if the patient has any cardiac history or risk factors before starting a new TCA

TCA plasma levels (therapeutic drug monitoring) can be ordered for desipramine, though optimal range is not definitively established; published ranges suggest 50–300 ng/mL

Patient Counseling Points During Supply Disruptions

Advise patients to refill 7–10 days before running out and to call the pharmacy in advance to check stock

Recommend independent pharmacies, which often stock less common generics or can order directly

Direct patients to medfinder.com/providers — a service that calls pharmacies on their behalf to find their medication

Counsel patients NEVER to abruptly stop desipramine — even a brief gap can cause withdrawal and clinical setback

Supporting Your Patients With medfinder

medfinder is a paid service that helps patients locate medications at pharmacies near them. Rather than calling multiple pharmacies, patients provide their medication, dose, and ZIP code — and medfinder calls pharmacies and texts back results. For providers, recommending medfinder can reduce patient frustration, reduce care gap calls to your office, and ensure patients stay on their medication without interruption.